Wednesday, November 18, 2026 Evidence-led medical research news
The First Cohort
Medical research, with the receipts
LM

Lena Marshall

Clinical trials · FDA · Oncology

A veteran health journalist who reads the trial before the press release. Ten years covering drug development, regulatory decisions, and oncology — now writing independently for The First Cohort.

Nutrition & Food

Vitamin B12 Rescued Worms With a Rare Childhood-Disease Mutation, and Patients Run Short of the Molecule It Helps Make

Eight Verheij syndrome patients had about 85 percent less methionine in their blood than controls, the molecule a B12-dependent enzyme regenerates. The vitamin was tested in worms, not in them.

Cancer

After 16 Years of 'Talk to Your Doctor,' the American Cancer Society Tells Men 50 to 69 to Get a PSA Test

Distant-stage prostate cancer is rising 6 percent a year in men 55 and older, and the long screening trials now show deaths prevented. The cancer society moved. The federal task force has not.

Drugs & FDA

Inovio's Accelerated-Approval Drug Is Headed for a $460,000 List Price, Matching the Rival the FDA Approved Outright

Inovio expects to list Voceryq at about $115,000 a dose, the same as Precigen's fully approved Papzimeos, then raised about $80.5 million in stock while the trial meant to confirm its benefit still lacks a final protocol.

Drugs & FDA

Bayer's New Stroke Drug Raised Bleeding in the Same 90 Days Its Trial Couldn't Prove a Stroke Benefit

Sunharbo cut ischemic strokes by 2.2 percentage points over a median 567 days. In the first 90 days its stroke benefit missed statistical significance, and the FDA says major bleeding went up.

Autoimmune & Inflammation

A Vitamin-Aisle Cholesterol Supplement Eased Psoriasis in a Small Trial, Most of All in Patients With High Cholesterol

Pantethine, a vitamin B5 derivative sold to people watching their cholesterol, quieted the immune cells behind psoriasis in mice. In a 24-patient pilot, the benefit clustered in the patients whose cholesterol was already high.

Autoimmune & Inflammation

An Experimental Asthma Drug Blocks a Signal That, in Fish, Guards the Gut

Zebrafish missing the 5-oxoETE receptor developed gut inflammation with no infection. A blocker of that receptor, covered by a patent application, had already been tested in monkeys.

Cancer

Blood Banked Years Before Diagnosis Ties PFOA to a 67 Percent Higher Rate of ER-Negative Breast Cancer

Women with the most PFOA in their blood had a 67 percent higher rate of the breast cancer that hormone drugs can't touch, as EPA weighs letting some water systems wait until 2031.

Drugs & FDA

FDA Fast-Tracks a J&J Head and Neck Cancer Drug on Tumor Shrinkage, and Its Announcement Names No Confirmatory Trial

Tumors shrank in 42 percent of patients in a 102-person trial with no control arm. The FDA says clinical benefit is unconfirmed and confirmatory studies are required, and its announcement does not name one.

Drugs & FDA

Edwards' Case for Earlier Heart Valves Rests on Hospital Stays, Not Survival

Edwards' own trial halved the share of moderate aortic stenosis patients hospitalized for heart failure, but deaths ran 8.4 percent with early TAVR versus 7.3 percent under initial surveillance, and 57.4 percent of that arm got the valve within two years anyway.

Brain & Aging

Alzheimer's "DNA Repair" Drug Rests on Three Mice per Group and No Memory Test

An experimental compound sold as a new Alzheimer's drug was injected into three male mice per group, and none of them took a memory test. Human dosing so far has lasted at most a week, in men aged 19 to 45.

Cancer

The Lymphoma Combination With an 'Acceptable Safety Profile' Lost to Its Control Arm

Some oncologists want second opinions to stop steering patients away from trials. Vinay Prasad answered with venetoclax: in its randomized double-hit lymphoma cohort, estimated two-year survival was 52 percent with the drug and 72 percent without it.

Investigations

The NIH Hospital Board Chair Who Rebuked Kennedy's Vaccine-Injury Clinic Has Counseled Pfizer, Merck and Sanofi

The Times quoted Jack Leslie's rebuke of the NIH vaccine-injury clinic and called him a former PR chairman. It left out his current Weber Shandwick job and the deputy director's answer.

Nutrition & Food

Norwegian Data Tie Mood Swings to Comfort Eating Between Six and Twelve, Not the Teenage Years the Headline Promised

In 878 Norwegian children, getting moodier than usual between six and ten predicted more comfort eating two years later. From age 12 on, the same link did not show up, though the press coverage put the risk in adolescence.

Infectious Disease

Israel's Split-Vaccine Study Has a Problem: 63 Percent of Children on the Ministry's Own Measles Shot Were Late

Of nearly 500,000 Israeli children, 2,933 got single-antigen measles shots instead of MMRV. Most of the children who received the ministry's recommended MMRV shot were vaccinated more than five weeks late anyway.

Drugs & FDA

Inovio Gets Its First FDA Approval After 7 of 26 Patients Went a Year Without Surgery

In December, the FDA's preliminary view was that Inovio hadn't justified the accelerated pathway. On Friday it granted it, on an uncontrolled trial whose confirmatory study still has no agreed protocol.

Cancer

Four Children's 'Non-High-Risk' Muscle Cancers Carried the Cell State of the Deadly Kind

Four children whose rhabdomyosarcomas lacked the gene fusion that marks the dangerous form died anyway. Read one cell at a time, their tumors shared a gene-activity state with the high-risk disease.

Investigations

Clinicians Have Asked an Ad-Funded AI 271 Million Questions, and Most Patients Can't Say Whether It Touched Their Care

Sixty percent of Americans are uncomfortable with AI in their diagnosis and treatment, and 46 percent can't say whether a provider has used it in their care. One clinical AI platform, paid for partly by drug and device ads, has already logged 271 million clinician queries.

Cancer

A Glioblastoma 'Breakthrough' in October: Two Cell Lines, One Chip, and a Paper From April

Brain tumor cells grown for a month in thickened fluid moved faster and kept some of the changes, but only in two lab lines, which disagreed with each other, and nothing here has touched a patient.

Cancer

A 443,451-Cell Map Finds Pancreatic Tumors Are Crowds, Not Types

Inside one pancreatic tumor, NYU and UC San Diego researchers found as many as 11 distinct clones, which muddies the subtype label used to choose chemotherapy. The drug targets they point to next arrive with a history.

Cancer

Norway's Own Screening Adviser Ran the Numbers: About One in 86 Screened Women Overdiagnosed

By its own adviser's estimate, Norway's mammography program overdiagnoses about one in 86 screened women, roughly three for every breast cancer death it prevents, while a 58-trial review finds early detection is no reliable stand-in for fewer deaths.

Cancer

Roche's KRAS Pill Beat the Older Drugs on Survival, an Endpoint Lumakras Never Won Against Chemotherapy

Median survival ran 17.7 months on divarasib and 12.0 on a control arm that was nine-tenths Lumakras, a drug whose own confirmatory trial showed no survival edge over chemotherapy.

Cancer

Mayo's Pancreatic Cancer AI Also Flags One Cancer-Free Scan in Five

Mayo's REDMOD caught 73 percent of pancreatic cancers on CT scans taken months before diagnosis, nearly double the radiologists' rate. It also flagged about 19 percent of cancer-free scans, and its lead researcher says it has not been tested at deployment prevalence.

Drugs & FDA

Heart Failure Admissions Ran 3.7 Percent Higher for Every Year the West Sold Legal Pot

Fifty million discharge records tie each year of Western dispensary sales to higher heart failure, heart attack and atrial fibrillation admission rates, while the federal rescheduling fight sits frozen before a DEA judge.

Cancer

Compass Plans to File a Biliary Cancer Drug Without the Survival Trial the FDA Asked For

Tovecimig plus chemotherapy shrank more biliary tract tumors than chemotherapy alone, but median survival was 8.9 months against 9.4, and 93.5 percent of the combination arm had grade 3 or worse adverse events. The FDA recommended a survival trial before filing. Compass plans to file anyway.